SBIR/STTR Research Award

Phase II: Development of a Neurovascular Magnetic Particle Imaging system with sub-millimeter resolution and real time speed for non-radiative 3D perfusion angiography

Award identifier 6e33b749a4b4ac4853d314957668ceb94d1478aabc9df52f98b6d28a5ae8b0f0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,825,551

Program and phase

SBIR · Phase II

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MAGNETIC INSIGHT, INC
Proposal award date
2019-01-15
Contract end date
2020-12-31
UEI
HY76TZ1Z48X4
Solicitation number
PA18-574
Topic code
NIDA

Research abstract

Abstract Clinicians rely on neuroimaging to visualize life-changing diseases affecting the brain. Current techniques struggle in areas important for neuroimaging such as quantifying cerebrovascular disease, detecting diseases of inflammation, and monitoring newly developed cell-based therapies. This is due to fundamental technical limitations in MRI, CT, and nuclear medicine. For example, CT perfusion imaging suffers from intrinsically poor signal-to-noise ratio (SNR), which translates to low image resolution and poor quantification that prevents identification of smaller strokes and vasospasms. A new clinical modality that provides fundamentally new information would present new opportunities for medicine. Magnetic Particle Imaging (MPI) is an emerging tracer imaging technology that excels at detecting functional measures such as perfusion. The MPI technique directly images superparamagnetic iron oxide (SPIO) tracers by measuring their time-varying magnetization in response to safe, low-frequency magnetic fields. MPI images are direct views of tracer distribution with no signal arising from tissue, no perturbations from materials such as air, and image intensity that is directly linear with tracer concentration. This “hot-spot” contrast provides spatial localization and quantification without ambiguity. In clinical neuroimaging, MPI can be used for real-time quantitative perfusion imaging, measurement of cerebrovascular reserve, and assessing vessel lumen diameters. MPI excels at measuring dynamic contrast enhancement and enhanced permeability and retention in tumors, and MPIandapos;s properties are near-ideal for cell tracking. In Phase I we explored multiple clinical magnet designs, estimated system cost, developed a manufacturing plan, and manufactured a small-scale preclinical system. In Phase II, we propose building the first human MPI imager. We will build the main magnet, characterize its magnetic performance, integrate all necessary support systems (shielding, RF transmit and receive, magnet control systems, etc.), characterizing the imager with phantoms, and finally evaluate with animal cadavers.Narrative Magnetic Particle Imaging (MPI) is a new imaging modality whose unique contrast, safety, and speed solves several limitations and concerns of current neurovascular imaging protocols. Here we propose to develop the first cerebrovascular MPI imager offering an alternative and new modality to allow safe assessment, staging and monitoring of neurovascular diseases such as stroke, aneurism and other vaso-malformations. Successful completion of a human brain MPI imager will mark the beginning of a new field of diagnostic imaging comparable in scope to the introduction of MRI, CT, or Ultrasound.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2015–2023). Reported award amounts total $10,100,200. Reported amounts are not federal obligations.

Phases: Phase II, Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.